Iovance Biotherapeutics Inc
Set by 24/7 Wall St.’s proprietary analysis of professional targets, profit trajectory, sector, risk, and retail attention. How we calculate our price targets →
Analyst Sentiment
Iovance Biotherapeutics appears attractively valued at current levels. With a 20.6% upside to our $12.15 target, the risk-reward profile looks favorable for investors with a 12-month time horizon. Wall Street agrees, with 78% of analysts rating it a Buy.
The 24/7 Factor
5-Year Projection
Prediction History
| Date | Price Target | Stock Price | Rating | Upside |
|---|---|---|---|---|
| $12.42 | $8.60 | BUY | +44.4% | |
| $12.41 | $8.79 | BUY | +41.2% | |
| $12.44 | $8.01 | BUY | +55.3% | |
| $11.46 | $8.29 | BUY | +38.2% | |
| $11.45 | $6.98 | BUY | +64.1% | |
| $11.14 | $4.34 | BUY | +156.7% | |
| $10.82 | $4.07 | BUY | +166.0% | |
| $10.82 | $5.14 | BUY | +110.8% |
Frequently Asked Questions
What is the IOVA stock price prediction for 2030?
Looking ahead to 2030, our model projects IOVA could trade at an average price of $15.90, with a potential range between $11.92 and $19.87. This represents a potential 57.8% return from today’s price. Long-term forecasts depend heavily on company execution, competitive dynamics, and broader market conditions.
Is IOVA a buy, sell, or hold right now?
24/7 Wall St. currently rates IOVA as a BUY. Strong upside (+20.6%) Among Wall Street analysts, 7 rate it Buy, 2 rate it Hold, and 0 rate it Sell.
What is the IOVA stock price target in an optimistic scenario?
In our optimistic scenario for IOVA, the stock could reach $13.94 over the next 12 months, representing a 38.4% gain from today’s price. This scenario assumes favorable conditions materialize, including strong earnings growth, positive market sentiment, and successful execution of company initiatives.
What is the downside risk for IOVA stock?
In our conservative scenario, IOVA could trade as low as $8.98 over the next 12 months, representing a 10.9% decline from current levels. This scenario accounts for potential headwinds including earnings misses, competitive pressures, or broader market weakness.
Projections are estimates based on current data, updated daily. Not investment advice. Learn how we calculate these projections →